Assetmark Inc. Has $69,000 Stake in Insulet Co. (NASDAQ:PODD)

Assetmark Inc. increased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 1,447.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 263 shares of the medical instruments supplier’s stock after purchasing an additional 246 shares during the quarter. Assetmark Inc.’s holdings in Insulet were worth $69,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. SBI Securities Co. Ltd. bought a new position in shares of Insulet in the fourth quarter valued at about $36,000. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Insulet by 30.1% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock worth $2,192,000 after acquiring an additional 1,942 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Insulet by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after purchasing an additional 3,113 shares during the last quarter. Orion Portfolio Solutions LLC lifted its stake in shares of Insulet by 86.2% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock valued at $1,822,000 after acquiring an additional 3,623 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. grew its position in Insulet by 5.7% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock worth $35,708,000 after acquiring an additional 8,301 shares during the last quarter.

Insider Activity at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.47% of the stock is owned by company insiders.

Insulet Price Performance

Shares of NASDAQ PODD opened at $255.44 on Friday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm’s 50-day simple moving average is $272.54 and its 200 day simple moving average is $254.96. The stock has a market cap of $17.94 billion, a price-to-earnings ratio of 44.12, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PODD shares. Stifel Nicolaus increased their target price on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Citigroup lifted their target price on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. StockNews.com cut shares of Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Wells Fargo & Company lifted their price target on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Raymond James restated an “outperform” rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.